Seminal Trials: IPASS for EGFR NSCLC

In this special episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Narjust Florez discuss the seminal IPASS trial with its principal investigator, Dr. Tony Mok. IPASS was a randomized phase III trial that compared the EGFR TKI gefitinib to carboplatin plus paclitaxel and showed, for the first time, that in a selected population, targeted therapy was superior to chemotherapy. The initial results were published in the New England Journal of Medicine in 2009 and helped usher in the era of precision oncology. Dr. Tony Mok is the Li Shu Fan Medical Foundation Endowed Professor and Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong. He co-founded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group, and Asia Thoracic Oncology Research Group.